A Phase 3, Randomized, Open-label, Multicenter Study Comparing Ponatinib Versus Imatinib, Administered in Combination With Reduced-Intensity Chemotherapy, in Patients With Newly Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia

E
Elizabeth Martin

Primary Investigator

Recruiting
18 years - 100 years
All
1 Location

Brief description of study

The primary objective of the study is to compare the efficacy of ponatinib versus imatinib, administered as first-line therapy in combination with reduced-intensity chemotherapy, in patients with newly diagnosed Ph+ ALL, as measured by the MRD-negative CR rate at the end of induction

Eligibility of study

You may be eligible for this study if you meet the following criteria:

  • Conditions: Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (Ph+ ALL)
  • Age: 18 years - 100 years
  • Gender: All

In order to be eligible to take part in this trial, patients must meet the following criteria:

  • Newly diagnosed Philadelphia chromosome-positive (Ph+) or BCR-ABL1-positive ALL, as defined by the 2017 national comprehensive cancer network (NCCN) guidelines.
  • Cannot have any active serious infection requiring antibiotics within 14 days before the first dose of study drug.

For a full list of participation criteria, please visit clinicaltrials.gov.

Updated on 01 Aug 2024. Study ID: TX10562

Find a site

We have submitted the contact information you provided to the research team at {{SITE_NAME}}. A copy of the message has been sent to your email for your records.
Would you like to be notified about other trials? Sign up for Patient Notification Services.
Sign up

Send a message

Enter your contact details to connect with study team

Investigator Avatar

Primary Contact

First name*
Last name*
Email*
Phone number*
Other language

Interested in the study?

Select a study center that’s convenient for you, and get in touch with the study team.

Contact a study center